Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis
Michael P Pender, Peter A Csurhes, Jacqueline M Burrows, Scott R Burrows, Michael P Pender, Peter A Csurhes, Jacqueline M Burrows, Scott R Burrows
Abstract
Mounting evidence indicates that infection with Epstein-Barr virus (EBV) has a major role in the pathogenesis of multiple sclerosis (MS). Defective elimination of EBV-infected B cells by CD8+ T cells might cause MS by allowing EBV-infected autoreactive B cells to accumulate in the brain. Here we undertake a comprehensive analysis of the T-cell response to EBV in MS, using flow cytometry and intracellular IFN-γ staining to measure T-cell responses to EBV-infected autologous lymphoblastoid cell lines and pools of human leukocyte antigen (HLA)-class-I-restricted peptides from EBV lytic or latent proteins and cytomegalovirus (CMV), in 95 patients and 56 EBV-seropositive healthy subjects. In 20 HLA-A2+ healthy subjects and 20 HLA-A2+ patients we also analysed CD8+ T cells specific for individual peptides, measured by binding to HLA-peptide complexes and production of IFN-γ, TNF-α and IL-2. We found a decreased CD8+ T-cell response to EBV lytic, but not CMV lytic, antigens at the onset of MS and at all subsequent disease stages. CD8+ T cells directed against EBV latent antigens were increased but had reduced cytokine polyfunctionality indicating T-cell exhaustion. During attacks the EBV-specific CD4+ and CD8+ T-cell populations expanded, with increased functionality of latent-specific CD8+ T cells. With increasing disease duration, EBV-specific CD4+ and CD8+ T cells progressively declined, consistent with T-cell exhaustion. The anti-EBNA1 IgG titre correlated inversely with the EBV-specific CD8+ T-cell frequency. We postulate that defective CD8+ T-cell control of EBV reactivation leads to an expanded population of latently infected cells, including autoreactive B cells.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
- Ascherio A, Munger KL, Lünemann JD. The initiation and prevention of multiple sclerosis. Nat Rev Neurol 2012; 8: 602–612.
- Pender MP, Burrows SR. Epstein–Barr virus and multiple sclerosis: potential opportunities for immunotherapy. Clin Transl Immunol 2014; 3: e27.
- Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350: 1328–1337.
- Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 2005; 79: 1296–1307.
- Hadinoto V, Shapiro M, Sun CC, Thorley-Lawson DA. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog 2009; 5: e1000496.
- Hawkins JB, Delgado-Eckert E, Thorley-Lawson DA, Shapiro M. The cycle of EBV infection explains persistence, the sizes of the infected cell populations and which come under CTL regulation. PLoS Pathog 2013; 9: e1003685.
- Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol 2000; 54: 19–48.
- Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007; 25: 587–617.
- Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003; 24: 584–588.
- Pender MP. The essential role of Epstein–Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist 2011; 17: 351–367.
- Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708–712.
- Amyes E, McMichael AJ, Callan MFC. Human CD4+ T cells are predominantly distributed among six phenotypically and functionally distinct subsets. J Immunol 2005; 175: 5765–5773.
- Pender MP, Csurhes PA, Pfluger CMM, Burrows SR. Deficiency of CD8+ effector memory T cells is an early and persistent feature of multiple sclerosis. Mult Scler 2014; 20: 1825–1832.
- Bergmann CC, Altman JD, Hinton D, Stohlman SA. Inverted immunodominance and impaired cytolytic function of CD8+ T cells during viral persistence in the central nervous system. J Immunol 1999; 163: 3379–3387.
- Ifergan I, Kebir H, Alvarez JI, Marceau G, Bernard M, Bourbonnière L et al. Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on α4 integrin. Brain 2011; 134: 3560–3577.
- Craig JC, Haire M, Millar JHD, Fraser KB, Merrett JD. Immunological control of Epstein–Barr virus-transformed lymphocytes in multiple sclerosis. Clin Immunol Immunopathol 1983; 29: 86–93.
- Craig JC, Hawkins SA, Swallow MW, Lyttle JA, Patterson VH, Merrett JD et al. Subsets of T lymphocytes in relation to T lymphocyte function in multiple sclerosis. Clin Exp Immunol 1985; 61: 548–555.
- Craig JC, Haire M, Merrett JD. T-cell-mediated suppression of Epstein-Barr virus-induced B lymphocyte activation in multiple sclerosis. Clin Immunol Immunopathol 1988; 48: 253–260.
- Pender MP, Csurhes PA, Lenarczyk A, Pfluger CMM, Burrows SR. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80: 498–505.
- Lindsey JW, Hatfield LM. Epstein-Barr virus and multiple sclerosis: cellular immune response and cross-reactivity. J Neuroimmunol 2010; 229: 238–242.
- Jilek S, Schluep M, Harari A, Canales M, Lysandropoulos A, Zekeridou A et al. HLA-B7-restricted EBV-specific CD8+ T cells are dysregulated in multiple sclerosis. J Immunol 2012; 188: 4671–4680.
- Gronen F, Ruprecht K, Weissbrich B, Klinker E, Kroner A, Hofstetter HH et al. Frequency analysis of HLA-B7-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes in patients with multiple sclerosis and healthy controls. J Neuroimmunol 2006; 180: 185–192.
- Höllsberg P, Hansen HJ, Haahr S. Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin Exp Immunol 2003; 132: 137–143.
- Cepok S, Zhou D, Srivastava R, Nessler S, Stei S, Büssow K et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 2005; 115: 1352–1360.
- Lünemann JD, Edwards N, Muraro PA, Hayashi S, Cohen JI, Münz C et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 2006; 129: 1493–1506.
- Jilek S, Schluep M, Meylan P, Vingerhoets F, Guignard L, Monney A et al. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 2008; 131: 1712–1721.
- Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B et al. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog 2013; 9: e1003220.
- Pudney VA, Leese AM, Rickinson AB, Hislop AD. CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med 2005; 201: 349–360.
- Tynan FE, Elhassen D, Purcell AW, Burrows JM, Borg NA, Miles JJ et al. The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation. J Exp Med 2005; 202: 1249–1260.
- Pender MP, Csurhes PA, Pfluger CMM, Burrows SR. CD8+ T cells far predominate over CD4+ T cells in healthy immune response to Epstein-Barr virus infected lymphoblastoid cell lines. Blood 2012; 120: 5085–5087.
- Brynedal B, Duvefelt K, Jonasdottir G, Roos IM, Åkesson E, Palmgren J et al. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS ONE 2007; 2: e664.
- Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 2010; 133: 1914–1929.
- Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003; 77: 4911–4927.
- Kahan SM, Wherry EJ, Zajac AJ. T cell exhaustion during persistent viral infections. Virology 2015; 479–480: 180–193.
- Larsen M, Sauce D, Arnaud L, Fastenackels S, Appay V, Gorochov G. Evaluating cellular polyfunctionality with a novel polyfunctionality index. PLoS ONE 2012; 7: e42403.
- Ryan JL, Fan H, Glaser SL, Schichman SA, Raab-Traub N, Gulley ML. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. J Mol Diagn 2004; 6: 378–385.
- Yea C, Tellier R, Chong P, Westmacott G, Marrie RA, Bar-Or A et al. Epstein-Barr virus in oral shedding of children with multiple sclerosis. Neurology 2013; 81: 1392–1399.
- Hopwood PA, Brooks L, Parratt R, Hunt BJ, Maria B, Alero TJ et al. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients. Transplantation 2002; 74: 194–202.
- Alfieri C, Birkenbach M, Kieff E. Early events in Epstein–Barr virus infection of human B lymphocytes. Virology 1991; 181: 595–608.
- Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007; 204: 2899–2912.
- Fraser KB, Millar JHD, Haire M, McCrea S. Increased tendency to spontaneous in-vitro lymphocyte transformation in clinically active multiple sclerosis. Lancet 1979; 314: 715–717.
- Munch M, Møller-Larsen A, Christensen T, Morling N, Hansen HJ, Haahr S. B-lymphoblastoid cell lines from multiple sclerosis patients and a healthy control producing a putative new human retrovirus and Epstein–Barr virus. Mult Scler 1995; 1: 78–81.
- Tørring C, Andreasen C, Gehr N, Bjerg L, Petersen T, Höllsberg P. Higher incidence of Epstein–Barr virus-induced lymphocyte transformation in multiple sclerosis. Acta Neurol Scand 2014; 130: 90–96.
- Tzartos JS, Khan G, Vossenkamper A, Cruz-Sadaba M, Lonardi S, Sefia E et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 2012; 78: 15–23.
- Serafini B, Muzio L, Rosicarelli B, Aloisi F. Radioactive in situ hybridization for Epstein-Barr virus-encoded small RNA supports presence of Epstein-Barr virus in the multiple sclerosis brain. Brain 2013; 136: e233.
- Latham LB, Lee MJ, Lincoln JA, Ji N, Forsthuber TG, Lindsey JW. Antivirus immune activity in multiple sclerosis correlates with MRI activity. Acta Neurol Scand 2016; 133: 17–24.
- Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985; 325: 1313–1315.
- Panitch HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994; 36: S25–S28.
- Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 2006; 67: 652–659.
- Aalto SM, Linnavuori K, Peltola H, Vuori E, Weissbrich B, Schubert J et al. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. J Med Virol 1998; 56: 186–191.
- Donati D, Espmark E, Kironde F, Mbidde EK, Kamya M, Lundkvist Å et al. Clearance of circulating Epstein-Barr virus DNA in children with acute malaria after antimalaria treatment. J Infect Dis 2006; 193: 971–977.
- Tuuminen T, Kekäläinen E, Mäkelä S, Ala-Houhala I, Ennis FA, Hedman K et al. Human CD8+ T cell memory generation in Puumala hantavirus infection occurs after the acute phase and is associated with boosting of EBV-specific CD8+ memory T cells. J Immunol 2007; 179: 1988–1995.
- Ueda S, Uchiyama S, Azzi T, Gysin C, Berger C, Bernasconi M et al. Oropharyngeal Group A streptococcal colonization disrupts latent Epstein-Barr virus infection. J Infect Dis 2014; 209: 255–264.
- Walton AH, Muenzer JT, Rasche D, Boomer JS, Sato B, Brownstein BH et al. Reactivation of multiple viruses in patients with sepsis. PLoS ONE 2014; 9: e98819.
- Pender MP, Csurhes PA, Greer JM, Mowat PD, Henderson RD, Cameron KD et al. Surges of increased T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects. J Immunol 2000; 165: 5322–5331.
- Farez MF, Correale J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol 2011; 68: 1267–1271.
- Gudgeon NH, Taylor GS, Long HM, Haigh TA, Rickinson AB. Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity. J Virol 2005; 79: 5477–5488.
- West EE, Youngblood B, Tan WG, Jin H-T, Araki K, Alexe G et al. Tight regulation of memory CD8+ T cells limits their effectiveness during sustained high viral load. Immunity 2011; 35: 285–298.
- Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 2005; 202: 637–650.
- Wandinger K-P, Wessel K, Neustock P, Siekhaus A, Kirchner H. Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis. J Neurol Sci 1997; 149: 87–93.
- Stasiolek M, Bayas A, Kruse N, Wieczarkowiecz A, Toyka KV, Gold R et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 2006; 129: 1293–1305.
- Klenerman P, Oxenius A. T cell responses to cytomegalovirus. Nat Rev Immunol 2016; 16: 367–377.
- Lenman JAR, Peters TJ. Herpes zoster and multiple sclerosis. Br Med J 1969; 2: 218–220.
- Berr C, Puel J, Clanet M, Ruidavets JB, Mas JL, Alperovitch A. Risk factors in multiple sclerosis: a population-based case-control study in Hautes-Pyrénées, France. Acta Neurol Scand 1989; 80: 46–50.
- Ross RT, Cheang M, Landry G, Klassen L, Doerksen K. Herpes zoster and multiple sclerosis. Can J Neurol Sci 1999; 26: 29–32.
- Kang J-H, Sheu J-J, Kao S, Lin H-C. Increased risk of multiple sclerosis following herpes zoster: a nationwide, population-based study. J Infect Dis 2011; 204: 188–192.
- Mackay LK, Long HM, Brooks JM, Taylor GS, Leung CS, Chen A et al. T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display. PLoS Pathog 2009; 5: e1000699.
- Lünemann JD, Tintoré M, Messmer B, Strowig T, Rovira A, Perkal H et al. Elevated Epstein–Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol 2010; 67: 159–169.
- Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernán MA, Olek MJ et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001; 286: 3083–3088.
- Sundström P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nyström L et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004; 62: 2277–2282.
- Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005; 293: 2496–2500.
- Levin LI, Munger KL, O’Reilly EJ, Falk KI, Ascherio A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 2010; 67: 824–830.
- Besson C, Amiel C, Le-Pendeven C, Brice P, Fermé C, Carde P et al. Positive correlation between Epstein-Barr virus viral load and anti-viral capsid immunoglobulin G titers determined for Hodgkin’s lymphoma patients and their relatives. J Clin Microbiol 2006; 44: 47–50.
- Jabs DA, Arnett FC, Bias WB, Beale MG. Familial abnormalities of lymphocyte function in a large Sjögren’s syndrome kindred. J Rheumatol 1986; 13: 320–326.
- Tosato G, Steinberg AD, Yarchoan R, Heilman CA, Pike SE, De Seau V et al. Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Invest 1984; 73: 1789–1795.
- Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA. EBV and systemic lupus erythematosus: a new perspective. J Immunol 2005; 174: 6599–6607.
- Croia C, Serafini B, Bombardieri M, Kelly S, Humby F, Severa M et al. Epstein–Barr virus persistence and infection of autoreactive plasma cells in synovial lymphoid structures in rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1559–1568.
- Croia C, Astorri E, Murray-Brown W, Willis A, Brokstad KA, Sutcliffe N et al. Implication of Epstein-Barr virus infection in disease-specific autoreactive B cell activation in ectopic lymphoid structures of Sjögren’s syndrome. Arthritis Rheumatol 2014; 66: 2545–2557.
- Pender MP, Csurhes PA, Smith C, Beagley L, Hooper KD, Raj M et al. Epstein–Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Mult Scler 2014; 20: 1541–1544.
- Polman CH, Reingold SC, Edan G, Filippi M, Hartung H-P, Kappos L et al. Diagnostic criteria for multiple sclerosis: 2005 Revisions to the ‘McDonald Criteria’. Ann Neurol 2005; 58: 840–846.
- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald Criteria. Ann Neurol 2011; 69: 292–302.
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.
- Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144–1151.
- Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004; 4: 725–738.
- Walker S, Fazou C, Crough T, Holdsworth R, Kiely P, Veale M et al. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis 2007; 9: 165–170.
Source: PubMed